Pain
Conference Coverage
Combination therapy may benefit patients with migraine
A retrospective chart review suggests adding an anti-CGRP antibody to onabotulinumtoxinA boosts benefit.
Opinion
Not your ordinary neuropathy
An exam reveals hyperesthesia of both feet, and a hemoglobin A1c level of 7.5.
From the Journals
NSAIDs don’t make COVID-19 worse in hospitalized patients
In a British study, hospitalized patients didn’t fare worse if they’d taken NSAIDs regularly before admission.
From the Journals
Transcranial brain stimulation can modulate placebo and nocebo experiences
It remains to be seen if this method could eventually alter chronic pain.
FDA/CDC
FDA OKs higher-dose naloxone nasal spray for opioid overdose
Kloxxado delivers 8 mg of naloxone into the nasal cavity, which is twice as much as the 4 mg of naloxone contained in Narcan.
Feature
The cloudy role of cannabis as a neuropsychiatric treatment
Medical cannabis has been made widely available to patients and has largely outpaced the clinical evidence.
From the Journals
Doctors more likely to prescribe opioids to COVID ‘long-haulers,’ raising addiction fears
The new study “suggests to me that many clinicians still don’t get it,” said Dr. Andrew Kolodny.
News from the FDA/CDC
FDA warning letters target OTC cannabidiol product claims for pain relief
The FDA sent warning letters to two manufacturers for illegal marketing of drugs containing cannabidiol (CBD) and a failure to comply with current...
From the Journals
Cannabinoids may pose death risk for older patients with COPD
All-cause mortality significantly increased in COPD patients aged 66 years and older after starting nabilone or dronabinol.
Conference Coverage
Opioid use common for pain in multiple sclerosis
“Better pain management treatment options, including nonpharmacological options, are needed for people with MS and pain.”
From the Journals
Opioids prescribed for diabetic neuropathy pain, against advice
Inappropriate first-line opioid use was found in more than 40% of patients, dropping over time but without a concurrent rise in use of recommended...